Cambridge Laboratories' tetrabenazine approved in Spain

Cambridge Laboratories, a privately-owned UK specialty drugmaker, says that its first and only approved product, tetrabenazine, has received marketing clearance in Spain. The company also announced that it has recently signed distribution agreements for tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand. The agent, which is known as Nitoman in Germany and other key European territories and Xenazine in the UK, USA and elsewhere, is approved for the chorea associated with Huntington's disease. Cambridge recently renegotiated its agreements with UCB in Spain and Portugal, giving the firm marketing rights to tetrabenazine for 10 years.